Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:CYAD
- CUSIP: N/A
- Web: www.celyad.com
Capitalization:- Market Cap: $435.61 million
- Outstanding Shares: 9,520,000
Average Prices:- 50 Day Moving Avg: $42.65
- 200 Day Moving Avg: $27.77
- 52 Week Range: $16.31 - $48.93
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -11.17
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $9.54 million
- Price / Sales: 44.91
- Book Value: $10.93 per share
- Price / Book: 4.12
Profitability:Debt:- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 7.57%
- Quick Ratio: 7.57%
Misc:- Average Volume: 2,236 shs.
- Beta: 1.69
- Short Ratio: 1.95
Frequently Asked Questions for Celyad SA (NASDAQ:CYAD)
What is Celyad SA's stock symbol?
Celyad SA trades on the NASDAQ under the ticker symbol "CYAD."
Are investors shorting Celyad SA?
Celyad SA saw a increase in short interest in May. As of May 15th, there was short interest totalling 4,307 shares, an increase of 152.0% from the April 28th total of 1,709 shares. Based on an average daily volume of 3,834 shares, the short-interest ratio is currently 1.1 days.
Who are some of Celyad SA's key competitors?
Some companies that are related to Celyad SA include Heron Therapeutics (HRTX), Cellectis SA (CLLS), TG Therapeutics (TGTX), Editas Medicine (EDIT), Enanta Pharmaceuticals (ENTA), Mesoblast Limited (MESO), CRISPR THERAPTC (CRSP), Inovio Pharmaceuticals (INO), Spectrum Pharmaceuticals (SPPI), WAVE Life Sciences (WVE), ANI Pharmaceuticals (ANIP), ImmunoGen (IMGN), AC Immune SA (ACIU), Arena Pharmaceuticals (ARNA), Agenus (AGEN), PDL BioPharma (PDLI), Adamas Pharmaceuticals (ADMS) and Concert Pharmaceuticals (CNCE).
Who are Celyad SA's key executives?
Celyad SA's management team includes the folowing people:
- Michel E J Lussier, Chairman of the Board, Co-Founder
- Christian Homsy MD, Member of the Executive Management Committee, Chief Executive Officer, Executive Director
- Patrick Jeanmart, Member of the Executive Management Committee, Chief Financial Officer
- Gaetane Metz, Chief Operating Officer
- Richard Mountfield, Vice President of Global Regulatory Affairs
- Peter De Waele, Member of the Executive Management Committee, Vice President - Research & Development
- Georges Rawadi, Vice President - Business Development
- Seron Aymeric, Program Manager
- Philippe Dechamps, Chief Legal Officer
- Roland Gordon-Beresford Ph.D., Regulatory Affairs and IP Director
When did Celyad SA IPO?
(CYAD) raised $99 million in an initial public offering on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.
Who owns Celyad SA stock?
Who bought Celyad SA stock? Who is buying Celyad SA stock?
How do I buy Celyad SA stock?
Shares of Celyad SA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celyad SA's stock price today?
One share of Celyad SA stock can currently be purchased for approximately $45.00.
MarketBeat Community Rating for Celyad SA (NASDAQ CYAD)MarketBeat's community ratings are surveys of what our community members think about Celyad SA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Celyad SA (NASDAQ:CYAD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Celyad SA (NASDAQ:CYAD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/7/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $95.00 | N/A |  |
| 12/1/2015 | Maxim Group | Reiterated Rating | Buy | | N/A | |
(Data available from 6/24/2015 forward)
Earnings History for Celyad SA (NASDAQ:CYAD)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Celyad SA (NASDAQ:CYAD)Current Year EPS Consensus Estimate: $-5.16 EPS
Next Year EPS Consensus Estimate: $-4.03 EPS
Dividend History for Celyad SA (NASDAQ:CYAD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Celyad SA (NASDAQ:CYAD)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Celyad SA (NASDAQ:CYAD)
Latest Headlines for Celyad SA (NASDAQ:CYAD)
| Source: |
|
Celyad SA (CYAD) Chart for Saturday, June, 24, 2017
